Expertise in
14
conditions

Dr. Joleen M. Hubbard

Oncology
Allina Health Piper Building Pharmacy
913 E 26th St, 
Minneapolis, MN 
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Allina Health Piper Building Pharmacy
913 E 26th St, 
Minneapolis, MN 

Overview

Joleen Hubbard is an Oncologist practicing medicine in Minneapolis, Minnesota.

Dr. Hubbard is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Hepato-Pancreato-Biliary Surgery.

She is actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 19 clinical trials. Dr. Hubbard is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

St Francis Regional Medical Center
Mercy Hospital
Abbott Northwestern Hospital
Allina United Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Allina Health Piper Building Pharmacy
913 E 26th St, Minneapolis, MN 55404

Additional Areas of Focus

Dr. Hubbard has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
View 9 Less Clinical Trials

106 Total Publications

Epigenomic profiling links IGF2 overexpression to anthracycline resistance in colorectal cancer organoids.
Epigenomic profiling links IGF2 overexpression to anthracycline resistance in colorectal cancer organoids.
Journal: JCI insight
Published: July 20, 2026
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

M Health Fairview Masonic Cancer Clinic

909 Fulton Street Southeast, 
Minneapolis, MN 
 (1.7 miles away)
612-676-4200
Languages Spoken:
English, French, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Emmanuel Antonarakis is an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Antonarakis is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, PIK3CA-Related Overgrowth Spectrum, Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Antonarakis is board certified in Medical Oncology: American Board Of Internal Medicine, 2009. Dr. Antonarakis is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

M Health Fairview Masonic Cancer Clinic

909 Fulton Street Southeast, 
Minneapolis, MN 
 (1.7 miles away)
612-676-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Skubitz is an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Skubitz is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Splenectomy. Dr. Skubitz is board certified in Medical Oncology: American Board Of Internal Medicine, 1985 and Internal Medicine: American Board Of Internal Medicine, 1979. Dr. Skubitz is currently accepting new patients.

Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Referral may be required

Childrens Home Care Pharmacy

2530 Chicago Ave, 
Minneapolis, MN 
 (0.1 miles away)
612-813-5940
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Yoav Messinger is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Messinger is highly rated in 13 conditions, according to our data. His clinical expertise encompasses DICER1 Syndrome, Sertoli-Leydig Cell Tumor, Pleuropulmonary Blastoma, Leydig Cell Testicular Tumor, and Bone Marrow Transplant. Dr. Messinger is currently accepting new patients.

Frequently Asked Questions about Dr. Joleen M. Hubbard

How do I make an appointment with Dr. Joleen M. Hubbard?

You can book an appointment with Dr. Joleen M. Hubbard by calling their office at 612-863-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joleen M. Hubbard a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joleen M. Hubbard is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joleen M. Hubbard specialize in?

While Dr. Joleen M. Hubbard is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Joleen M. Hubbard participate in research or clinical trials?

Yes. Dr. Joleen M. Hubbard has published 106 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Joleen M. Hubbard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joleen M. Hubbard accept my insurance?

Dr. Joleen M. Hubbard accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 612-863-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hubbard's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile